Literature DB >> 3698304

Isoforms of creatine kinase MM and MB in acute myocardial infarction: a clinical evaluation.

M Panteghini, C Cuccia, A Malchiodi, M Calarco, N Pagnoni.   

Abstract

Serum creatine kinase (CK, EC 2.7.3.2) isoenzymes MM and MB were resolved, respectively, into three (MM1, MM2, MM3) and two (MB1, MB2) isoforms (subforms derived from the same isoenzyme) by electrophoresis and the isoform patterns were determined in multiple sequential serum samples, timed from the onset of chest pain, from 58 patients with acute myocardial infarction (AMI). During the first 3 h after the onset of chest pain, the serum isoform activity resembled the pattern seen in normal volunteers. Specimens obtained 6 h after AMI showed predominantly MM3 and MB2 (45% and 11% of the total CK activity, respectively). Between 10 and 72 h, there was a gradual shift in which MM3, MM2 and MB2 decreased, while MM1 and MB1 increased. MB2 and MB1 disappeared from the pattern for samples collected after 24-48 h, while MM1 was always the most prominent band at the end of the observation period (66%, range 41-77%, at 48 h). These data suggest that a single determination of CK isoform pattern, drawn between 6 and 48 h after AMI, may provide an effective means of predicting the time of onset of necrosis. There were no significant differences in the CK isoform patterns according to infarct location and functional status of patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3698304     DOI: 10.1016/0009-8981(86)90093-8

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  2 in total

1.  Identification by isoelectric focusing of creatine kinase-MM isoforms in the plasma and striated muscle of pigs.

Authors:  F Doizé; L Deroth
Journal:  Vet Res Commun       Date:  1991       Impact factor: 2.459

2.  Characterization of MB creatine kinase isoform conversion in vitro and in vivo in dogs.

Authors:  J J Billadello; H L Fontanet; A W Strauss; D R Abendschein
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.